Introduction
Improvement of therapy in children with acute lymphoblastic leukaemia (ALL) has resulted in survival rates of over 70%-80%; however, 20%-30% of children ultimately still suffer from a relapse [1, 2] . Today many children probably receive a too intensive treatment and will suffer from unnecessary side-effects in the future. Toxicity may be limited and good survival rates maintained by further individualisation of therapy. Many clinical and biological potential prognostic factors have been evaluated and some are currently used, i.e., age at presentation, white blood cell count, immunophenotype, DNA-ploidy and chromosomal abnormalities. In routine patient care, such risk assessment is mostly performed at diagnosis. Additional techniques may allow better stratification of patients. It was clarified that the level of residual disease after induction therapy is a very important prognostic factor for ultimate outcome in childhood ALL [3] [4] [5] [6] [7] [8] [9] [10] [11] . The presence of high levels of MRD at the end of induction therapy is known to be strongly correlated with the occurrence of a relapse and, as such negativity in MRD testing is an important independent prognostic factor [3, 4, 10] . As a result the level of residual disease after induction of remission as determined by quantitative PCR or flow cytometry, might be used to identify patients at risk for relapse, and these data might be used to tailor treatment according to this risk factor. In addition, it seems to be possible to predict outcome on the basis of in vitro drugsensitivity testing [12] .
This report deals in particular with the advantages and disadvantages of PCR-based MRD detection. Four main questions continually recur. Is it possible to detect and quantify MRD in children with B-precursor ALL, and can this add to therapy-stratification and outcome of patients? Which targets can be used? Which timepoint is the most informative? And finally, what is the most simple and cost-effective assay for implementation into routine patient care?
After an introduction into paediatric ALL and the conventional risk factors, this article addresses these questions, focuses on the PCR technique for quantification, the advantages and disadvantages of the gene rearrangements and/or fusion transcripts as a target and deals with the optimal time-point of sampling for MRD detection.
Paediatric ALL and treatment
ALL is the most prevalent type of leukaemia among children and occurs in approximately 80% of patients [1, 2] , The majority of ALL patients suffers from precursor B-lineage ALL (80%), whereas 20% of patients have T-lineage ALL. B-lineage ALL can be divided from the immature form of pre-B-ALL to the more mature B-ALL. The most common form of ALL is B-precursor ALL. Treatment of ALL improved in the early 1960s by introduction of combination chemotherapy and in the early 1970s by prophylactic treatment of the central nervous system, leading to a better outcome. Nowadays, over 70% [13] of children achieve long-term survival and are cured. Many different treatment protocols are used all over the world. Most treatment regimens have the following backbone: induction therapy, CNS prophylaxis, intensification-consolidation and maintenance therapy. Total duration of treatment is two years. Treatment differs for the various types of leukaemia. In all protocols, CNS-directed therapy is included. Initially, high-risk patients were treated with cranial irradiation. Later, conscious of the undesired late effects of cranial radiation, high-dose methotrexate in combination with intrathecal medication was given instead. It has been shown that this way of treatment gives at least similar results with respect to CNS relapse rate [14] [15] [16] .
Diagnosis of ALL is in general based on morphological, cytochemical and immunological characteristics of the leukaemic cells in bone marrow (BM) and peripheral blood. Diagnosis of leukaemia is made if the percentage of blasts exceeds 25% of cells in the BM. Depending on the protocol, patients are classified into two or three branches: non-high risk, intermediate and high risk. Currently used prognostic parameters for increased risk of relapse are initial leucocyte count over 50 x 10 9 /l, the presence of a specific translocation such as t(4;ll), t(9;22), age <1 or > 10 years, organ enlargement, T-lineage immunophenotype and involvement of extramedullary sites at diagnosis.
Prognostic factors
A number of clinical and biologic presenting features can be used to estimate the relapse hazard in patients, but these are not completely conclusive. Donadieu et al. [17] proposed a classification of prognostic factors in three categories: (1) standard and reproducible, i.e., gender, age, white blood cell count (WBC), mediastinal involvement, cytogenetic features and immunophenotype; (2) standard but less reproducible, i.e., node, liver and spleen volume and % of marrow blasts during induction; (3) not standard and used by only a limited number of co-operative groups, i.e., DNA index, initial steroid sensitivity and expression of myeloid markers. Although these and other clinical prognostic factors have been helpful in defining patient subgroups with different risks of treatment failure, no factor or combination of factors has proved sufficiently accurate to identify consistently individual patients who will fail treatment. It has been attempted to develop uniform risk criteria based on age, WBC, immunophenotype, DNA index, cytogenetics, CNS status and early response to therapy. Consensus was only reached on the basis of age and WBC [18, 19] . Age between 2 and 10 years and lower white blood cell (WBC) count have been consistently associated with a favourable outcome in pediatric ALL [18] [19] [20] . Below the age of one year and increasing with age > 10, there was a progressive decline of survival rate [21] . In adults and adolescents increasing age remains a dominant prognostic factor. Cytogenetic features such as t(4;ll) and t(9;22) are classified as highrisk cases. TEL-AMU t(12;21) is a more frequently present translocation in children associated with favourable outcome, and this fusion gene is mostly found in patients with ages between two and five years suffering from B-precursor ALL. It has been known for a long time that hyperdiploidy is a major prognostic factor. It has been shown that a DNA index greater than 1.16, compatible with hyperdiploidy of the blasts, identifies a subgroup of ALL patients who have a favourable outcome, regardless of the presence of other clinical or biological features associated with higher relapse risk [22] . The addition of age and WBC counts permits identification of patient subgroups with intermediate and poor prognosis. However, there has always been debate about the cut-off value for high-versus low-risk patients; i.e., 25, 50 or 100 x 10 9 cells/1. Furthermore, it has also been found that prognostically unfavourable structural chromosome abnormalities, including translocations, occur less frequently in cases of hyperdiploid ALL. As such, flow-cytometric evaluation of the leukemic cell DNA content complements but does not replace the need for extensive cytogenetic analysis. In some studies the in vivo prednisolone reponse is used as a parameter for early treatment response. A poor prednisolone response characterized a group of patients who developed very early relapses. However, not only prednisolone monotherapy, but also response to multi chemotherapy [23] [24] [25] are important prognostic factors. They reflect the result of drug uptake and metabolism, expression of resistance genes, and possibly immunological factors. Although these and other clinical prognostic factors have been helpful in defining risk groups, no factor or combination of factors has proved sufficiently accurate to identify consistently individual patients who will fail treatment. This warrants investigation of new biological markers.
As stated, the clinical response of leukaemic cells to chemotherapy can be predicted by in vitro analysis of the cellular response of leukaemic cells at diagnosis using in vitro drugsensitivity assays, and the response in vivo can be measured by the kinetics of MRD at the end of induction therapy and during early follow-up. Cellular drug resistance is thought to be an important cause of induction failure and relapse, and has been shown to be a strong and independent prognostic factor in childhood ALL [12, [26] [27] [28] [29] . Some groups apply a chemosensitivity assay that uses methyl-thiazol-tetrazolium (MTT) dyes to select effective drugs, and the results can be analysed by spectro-photometry. In vitro drug resistance profiles of different leukaemia types reflect the empirically known clinical effectiveness of the different drugs in these subtypes. It has been shown that the MTT assay serves a reliable tool for patient stratification in patients with acute leukaemia [12, 30] , although the usefulness in drug selection is not proven. The advantage is that the MTT assay is quick and it is also a cheap assay. Results of drug sensitivity testing are available within five days post diagnosis. A disadvantage is that this assay is not routinely performed. Only few laboratories are experienced in the application of this assay. All studies have been retrospectively done and, recently, first prospective studies have been started.
Previous reports have shown that the detection of MRD at the end of induction can distinguish patients at high and low risk. It is an independent prognostic factor [31] and its value is at least as strong as hyperdiploidy [4, 10, 32, 33] . The most reliable methods of detecting MRD are PCR analysis of antigen receptor genes and/ or chromosomal fusion transcripts [4, 10, 34] and flowcytometric identification of leukaemia associated phenotypes (detecting aberrant protein-expression of the ALL cells) [35] [36] [37] . Both techniques can consistently detect one leukaemic cell among 10,000 or more normal bone marrow mononuclear cells. One of the aims of MRD investigators is to estimate the amount of residual disease, rather than to simply establish its presence. Immunologic methods are faster and better suited for quantitative measurement, although they are less sensititive in comparison with the PCR technique [35] [36] [37] . In these tests, leukaemia-associated immunophenotypes, as found on leukaemic cells but not on normal bone marrow cells, are determined by multiparameter flow cytometry, with various combinations of monoclonal antibodies and/or heterologous antisera conjugated to various fluorochromes [38, 39] . For each case, marker combinations allowing the detection of one leukaemic cell per 10 4 normal nucleated bone marrow cells or greater were selected at diagnosis and then applied during clinical remission. In some cases, the assay can be hampered by the occurrence of immunophenotypic changes during the course of the disease, which prevents the flow cytometric identification of residual leukemic cells with the set of markers identified at the time of diagnosis. Results with four-colour flow cytometry are promising and the possibilities to use more combinations enable identification of more patients (up to 90% of patients) [37] .
Amplification of antigen receptor genes in a polymerase chain reaction has made a quick and broad development in the past years and has shown to be very accurate in the prediction of outcome. This technique uses the unique patient-specific junctional regions of rearranged Ig/TCR genes as a target by which to detect the persistence of malignant clones during follow-up of the patient. Although this technique can reach a sensitivity of 1 malignant cell in 10 5 normal cells, clonal evolution may hamper detection of MRD. Until two years ago, most techniques were semi-quantitative, using dot blot hybridisation [10] . More quantitative assays, such as competitive PCR using an internal standard [6] and limiting dilution assay [40] , [41] have also been used. Limiting Dilution allows accurate quantification but its use is limited since it is an extremely laborious technique [42, 43] . Real-time quantitative PCR RQ-PCR) is a new technique, which is able to perform the PCR reaction and quantitative measurement of PCR product at the same time [44, 45] . The technique is sensitive and reproducible and in contrast with the limiting dilution assay (LDA) relatively simple and fast. Comparison of results of RQ-PCR with LDA has shown that both tests give similar results [45] . During real-time PCR, based on TaqMan technology, the 5'-3' nuclease activity of Taq DNA polymerase cleaves the hybridized probe and thereby separates the reported dye from the quencher dye, resulting in emission of a fluorescent signal that increases during each subsequent PCR cycle. The realtime detection of fluorescence intensity generates quantitative data based on the early cycles when the fidelity of PCR amplification is the highest. The only disadvantage is that expensive primer/probe combinations have to be used, which have to be specific for each patient. Recently, it was shown that it is possible to use primer/ probe combinations which consist of a patient-specific forward primer, with a germline consensus probe and reverse primer, specific for the family type of IGH/TCR gene rearrangement instead of specific probe and reverse primer for the patient [44, 46] . This will result in a more cost-effective method for quantification of MRD by RQ-PCR.
Immunophenotyping and PCR are two entirely independent ways by which to monitor MRD of leukaemic cells. Neale and co-workers [36] have shown that tandem application of flow cytometry and PCR may overcome the limitations of each technique. The two methods provided highly concordant measurements of MRD. They suggest that both techniques should used for universal monitoring of MRD in childhood ALL.
Detection of MRD by PCR

Choice of PCR targets
As mentioned before, two types of targets -gene rearrangements and fusion transcripts of chromosomal translocations -can be used for the detection of MRD by PCR. Rearrangements in immunoglobin and T-cell receptor genes result in a unique recombination of variable, diversity and joining gene segments. In 90% of patients it is possible to develop a patient-specific primer, based on the junctional region between these gene segments, which can be regarded as fingerprint-like sequences due to deletion and insertion of nucleotides during the rearrangement proces. A major drawback of these targets is instability. Oligoclonality in respect to antigen receptor genes is frequently encountered in B-precursor ALL. Multiple rearranged IGH bands on Southern blot analysis at diagnosis are found in 30%-^0% of patients [5, 7, 9, 47] . Although in the total group of ALL patients the frequency of TCR oligoclonality is about 20%, the stability of TCRD or TCRG rearrangements is comparable to that of the IGH locus [47] [48] [49] [50] . Immunoglobin kappa deleting element (IGKKde) mediated rearrangements seem to form a more stable target, however, it is applicable in only 50 % of the patients [51, 52] . The necessity of identifying several (preferably stable) PCR targets and developing clonespecific quantitative PCRs for these targets within a short time span after diagnosis will be one of the major logistic problems that have to be solved before one can perform MRD detection in a routine setting. It has been demonstrated that (at least in oligoclonal ALL) the relapse-causing subclones show different biological behaviour as early as the very beginning of the disease and are not selected during therapy by ongoing genetic events under chemotherapeutic pressure [47, 53, 54] . It was also shown that relapse in oligoclonal patients is caused by slow regressing therapy-resistant leukaemic cells already present at diagnosis, although these subclones are as yet undetectable at initial diagnosis. This stresses the importance of screening for oligoclonality at diagnosis and stresses the necessity of using at least two different antigen receptor gene rearrangements in each patient.
Most chromosomal aberrations have a low incidence (l%-5%), but the t(12;21)(pl3;q22) translocation TEL-AM LI is described as the most frequent genetic anomaly in childhood ALL's [55] [56] [57] [58] . Although t(12;21)(pl3,q22) is often not detected by classical cytogenetic banding techniques, it is noted in 12%-30% of childhood ALL series when tested by RT-PCR. The TEL-AML1-tramlocation defines a subgroup of paediatric ALL ranging from the age of 1 to 10 years, showing a B-precursor immunophenotype, a non-hyperdiploid DNA content and a favourable prognosis [58, 59] . In the first studies, it was even suggested that response to therapy in this group of patients was so excellent that relapse never occurred [55] [56] [57] . Nevertheless, more recent studies have shown that relapses do occur but are less frequent [58] [59] [60] [61] . MRD studies of the TEL-AML1 transcript in relapsed TEL-AML1 -positive patients in comparison with TEL-AMLJ-negative patients, have shown in all CCR cases that MRD at the end of induction was highly reduced to levels of 10~5, while the relapsed patients remained positive at the end of induction therapy [54] . This means that the detection of the TEL-AML1 translocation does not rule out a relapse later on and that quantification of MRD is still necessary. As a result, MRD is a more reliable method by which to identify patients who have a higher risk for relapse, even in those positive for TEL-AML1. Recent studies showed that results of quantification of the TEL-A MLI translocation by RT-RQ PCR are comparable to the clinically validated genomic PCR for antigen receptor rearrangements [62] . As a consequence, one might decide to replace the antigen receptor-based PCR by RT-t(12;21)-PCR, as this PCR is more convenient and cheaper for MRD analysis in t(12;21)-positive patients.
Ideal time-point of detection of MRD
Most studies support quantification of MRD at one single time-point, i.e., at the end of induction therapy. The study of van Dongen et al. [4] demonstrated that by monitoring the levels of MRD in 240 patients with B-lineage ALL using a semi-quantitative detection method (dot-blot), combined information on MRD from the first three months of treatment (time-point at the end of induction and before start of consolidation) distinguishes patients with good prognosis from those with poor prognosis. As most studies have analyzed MRD at consecutive time points starting from day 28, little is known about the relation between MRD detection at an earlier time point and prognosis. Some studies [63, 64] have looked at the day 15 time-point, but have performed only a cytomorphologic analysis of residual leukemic cells, which is far less sensitive in comparison with MRD analysis by PCR. Recently, Panzer-Grumayer et al. [65] showed that evaluation of MRD in childhood ALL by semi-quantitative molecular methods on day 15 of induction therapy can be implemented in their recently established MRD-based stratification. After only two weeks of treatment the authors were able to identify after a patient population of 20% with a low risk of relapse. However, for patients with high levels of day 15 MRD, only the MRD-based risk groups, as defined by later time-points, were predictive [64] . Analysis of gene rearrangements by RQ-PCR in 17 patients with B-precursor ALL has shown that quantitative MRD results at day 15 are already highly informative [66] . The slope of the disappearance curve of the leukaemic cells between diagnosis, day 15 and week 5 was significantly different in CCR versus relapsed patients, illustrating the different clearance of residual cells in relapsed versus CCR patients. Therefore, it might be possible to discriminate between good and poor risk patients at this very early time-point. Low risk patients might benefit from the least intensive treatment. However, it has to be investigated in larger prospective studies whether a clear cut-off level will indeed be found. Clinicians might prefer to perform stratification of therapy based on determination of MRD at two time points. These results suggest that, although the start of consolidation can be used as a second time-point, quantitative MRD results of day 15 are informative in this respect and the second time-point needed might be the end of induction therapy. The major advantage of this approach is the earlier availability of the prognostic information, and determination of the therapy needed to combat his/her leukaemia.
General discussion, future place of MRD
All prospective studies on PCR-based MRD, as performed in the last few years, confirm that MRD detection is strongly predictive for outcome. Assessment of MRD may help to evaluate the efficacy of therapy, predicts pending relapse, and, ultimately, permit individualization of therapeutic protocols. It is clear that antigen receptor gene rearrangements and certain chromosomal translocations can be used accurately for MRD detection in children with ALL. To withdraw the risk of oligoclonality, more targets should be chosen. The TEL-AML1 fusion transcript is the most common translocation in childhood ALL, and it has even been shown that it is possible to use this translocation in MRD stratification in TEL -A MLl -positive ALL patients in order to limit the laboratory preparations. It decreases work-load and costs of development of primers, facilitating a routine clinical application of PCR. Developments in new techniques, i.e., the previously described RQ-PCR, will be important in routine clinical application of PCR. The question remains which time-point is the most informative. Recent studies give strong evidence that the early time-points like two and five weeks after start of therapy can discriminate patients very accurately into high-and low-risk groups, although the large prospective study of Van Dongen et al. [4] recommends five and twelve weeks as ideal timepoints for MRD detection.
As we know that detection of MRD may have potential clinical value, it is most important to develop prospective studies which will enable analysis of stratifica-tion of treatment based on MRD results. Stratification of treatment can follow two pathways: on the one hand identification of patients at high risk resulting in an early change of more intense treatment. Prospective studies have to show whether (and which) treatment change at certain time-points, will contribute to a better survival. Few centres have started with stratification of patients based on MRD results at day 43, in intensifying treatment for patients with high levels of MRD. Secondly, MRD may be more meaningful in the identification of patients at low risk, in order to decrease treatment for patients who have undetectable levels of MRD resulting in a decrease of unnecessary side-effects of treatment.
In both options, it will be important to use assays that give results within a short time span and that are simple to perform in all treatment centers. Large prospective studies are needed to standardize and control the quality of PCR-based MRD detection in order to ascertain which therapy-change would benefit patients with high/ low risk ALL.
